Peptide research is expanding far beyond obesity, muscle growth and metabolic control. One of the more interesting new areas is cardiovascular disease, particularly heart failure. A compound now entering human research is NNC0537-1482, an experimental peptide-based analogue of C-type natriuretic peptide, or CNP. Rather than targeting appetite or glucose control, NNC0537-1482 is designed around a...Read More
Not all modern peptide development is focused on obesity, muscle or ageing. One of the most interesting recent examples comes from haematology. Rusfertide is a synthetic hepcidin-mimetic peptide designed to regulate how iron is distributed in the body and, in turn, reduce excessive red blood cell production. After years of clinical development, rusfertide reached a...Read More
Most emerging peptide discussions focus on obesity, metabolism or muscle. Navepegritide takes us into a very different area: skeletal growth and achondroplasia. Previously known as TransCon CNP, navepegritide is a long-acting form of C-type natriuretic peptide, or CNP, designed for once-weekly administration. It is being developed specifically for children with achondroplasia, the most common form...Read More
Pemvidutide is one of the more interesting late-stage peptide therapies currently being studied because its development has moved beyond obesity alone and into serious liver disease. It is an investigational once-weekly dual GLP-1 and glucagon receptor agonist peptide developed by Altimmune. As of 2026, pemvidutide has entered Phase 3 development for metabolic dysfunction-associated steatohepatitis, or...Read More
BPC-157 has been discussed online for years as a peptide associated with tissue repair, injury recovery and regenerative research. Until recently, however, one major problem remained: most of the evidence came from animal studies rather than controlled human trials. That is now beginning to change. In 2026, a formal randomised, double-blind, placebo-controlled Phase 2 trial...Read More
Zenagamtide is one of the more unusual next-generation obesity peptides now entering late-stage clinical development. Previously known as amycretin, zenagamtide is a single peptide molecule designed to activate both GLP-1 and amylin-related receptors. That gives it a different strategy from drugs such as semaglutide, which primarily target GLP-1, or tirzepatide, which targets GIP and GLP-1....Read More
Most GLP-1 medicines activate the same receptor. But they do not necessarily activate that receptor in exactly the same way. Ecnoglutide, also known as XW003, is a newer peptide-based GLP-1 receptor agonist designed around the concept of biased signalling. Rather than strongly activating every signalling pathway connected to the GLP-1 receptor, ecnoglutide preferentially activates the...Read More
Enicepatide is one of Roche’s most important emerging metabolic drug candidates. Previously known as CT-388 and also identified as RO7795068, enicepatide is an investigational once-weekly dual GLP-1/GIP receptor agonist being developed for obesity, overweight and type 2 diabetes. (genentech-medinfo) What makes it particularly interesting is that the programme has now moved beyond early proof-of-concept research....Read More
Most of the attention around emerging peptides currently focuses on obesity and metabolic control. But another area is becoming increasingly important: age-related loss of muscle mass and function. One peptide now attracting renewed research interest is Pyr-Apelin-13, a naturally occurring form of the signalling peptide apelin. In 2026, researchers published new preclinical work investigating Pyr-Apelin-13...Read More
Most of the attention around emerging peptides currently focuses on obesity and metabolic control. But another area is becoming increasingly important: age-related loss of muscle mass and function. One peptide now attracting renewed research interest is Pyr-Apelin-13, a naturally occurring form of the signalling peptide apelin. In 2026, researchers published new preclinical work investigating Pyr-Apelin-13...Read More
